Table 1.
Clinical features and treatment of BD patients at the time of the study and cumulative
| Characteristic | At time of the study | Cumulative |
|---|---|---|
| Clinical features: N = 23 |
|
|
| Disease duration in years (mean ± SD) |
15 ± 8 |
- |
| Deep vein thrombosis (%) |
0 |
4 |
| Disease activity, median (p25-p75) |
7 (2–18) |
- |
| Patients on active phase of disease (%) |
78 |
- |
| Genital ulcer (%) |
13 |
97 |
| Oral ulcer (%) |
52 |
100 |
| Skin lesion (%) |
43 |
90 |
| Vascular involvement (%) |
0 |
21 |
| Articular involvement (%) |
43 |
67 |
| Gastrointestinal involvement (%) |
30 |
32 |
| Ocular involvement (%) |
22 |
64 |
| Neurological involvement (%) |
43 |
72 |
| Treatments: |
|
|
| Prednisone (< 10 mg) (%) |
9 |
83 |
| Prednisone (> 10 mg) (%) |
18 |
87 |
| Cyclosporine (%) |
4 |
18 |
| Azathioprine (%) |
9 |
32 |
| Methotrexate (%) |
4 |
7 |
| Infliximab (%) |
4 |
3 |
| Rituximab (%) |
4 |
7 |
| Colchicine (%) | 17 | 86 |